Dr Merbl discusses her lab’s research at the 3rd EurocanPlatform Translational Research Course in profiling changes in post-translational modifications (PTM) which allows the precise characterisation of different cancer sub-types, looking at lung adenocarcinoma as an example. Previous work has focused on genomic and transcriptional changes whilst proteomics and the protein modification landscape has remained untouched.

She explores the significance this will have on clinical practise, what the next steps are, what obstacles exist to this work and what the eventual benefits will be.